Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge City, China.
Metrics to compare | 301277 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship301277PeersSector | |
---|---|---|---|---|
P/E Ratio | 35.3x | 30.5x | −0.5x | |
PEG Ratio | 14.29 | −0.16 | 0.00 | |
Price/Book | 3.8x | 3.2x | 2.6x | |
Price / LTM Sales | 8.1x | 4.8x | 3.3x | |
Upside (Analyst Target) | - | 15.7% | 42.9% | |
Fair Value Upside | Unlock | 1.3% | 6.2% | Unlock |